Market research
RUBY Rubius Therapeutics Inc
PINK USD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- Not available
- Beta
- 2.21
Profile
Company facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US78116T1034
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- Not available
- Beta
- 2.21
About
About Rubius Therapeutics Inc
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RUBY discussion.
5 years, 4 months ago
Rubius Therapeutics, Inc is currently in a long term uptrend where the price is trading 58.7% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Rubius Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 8.8% to $-41M since the same quarter in the previous year.
Finally, its free cash flow grew by 25.3% to $-32M since the same quarter in the previous year.
Based on the above factors, Rubius Therapeutics, Inc gets an overall score of 4/5.